Institute Oncologic del Valles
Institute Oncologic del Valles
Algara M.,University Pompeu Fabra |
Arenas M.,Hospital Universitari Sant Joan Of Reus |
Arenas M.,Rovira i Virgili University |
Reyes V.,Hospital Universitari Vall dHebron |
And 10 more authors.
Radiotherapy and Oncology | Year: 2017
Background and purpose: Radiation oncology guidelines favour hypofractionated whole-breast radiotherapy (HWBRT) over more conventional schemes in the conservative treatment of breast cancer, but its adoption still varies in clinical practice. This study assessed the patterns of HWBRT adoption in Catalonia (Spain). Material and methods: We used a mixed-methods approach based on an explanatory sequential design, first collecting and analysing quantitative data on HWBRT use (>2.5. Gy per fraction) in 11 public radiotherapy centres (2005-2015) and then performing 25 semi-structured interviews with all department heads and reference radiation oncologist/s. Results: Of the 34,859 patients fulfiling the study criteria over the study period, just 12% were hypofractionated, reaching a percentage of 29% in 2015 (p <. 0.001). Our analysis showed a narrowing age gap between patients receiving conventional fractionation and hypofractionation in centres leading adoption. However, there were important differences in clinicians' interpretation of evidence (e.g. regarding the perceived risk of long-term toxicity) and selection of patients for specific indications, both within and between departments. Conclusions: Differences observed in the rate of adoption of HWBRT could not be tackled only using a rational, evidence-based approach. Factors related to the management of radiotherapy departments play a major role in the diffusion of therapeutic strategies. © 2017 Elsevier B.V.
Leon C.,Institute Oncologic del Vall |
Mirapeix R.,Institute Oncologic del Vall |
Blasco T.,Autonomous University of Barcelona |
Arcusa A.,Institute Oncologic del Valles |
And 2 more authors.
Psicooncologia | Year: 2013
Purpose: To compare the effectiveness of a Mindfulness-Based Stress Reduction (MBSR) intervention versus a psychoeducational standard intervention in oncological patients. Method: MBSR intervention was applied following a 2'5 h-session schedule, across 10 weekly sessions. Patients (n= 20) had to practice mindfulness daily at home during 45 minutes. In the psychoeducational group (n=17) a schedule of 8 weeekly sessions of 2'5 h each was applied. Following a pre-post design, the following questionnaires were applied to both groups of patients: STAI (to assess both state and trait anxiety), BDI (Depression) and EORTC-QLQ-C-30 (quality of life). Results: In the MBSR group, scores in anxiety and depression decreased at post-treatment assessment whereas quality of life scores increased. These differences reached statistical significance. In the psychoeducational group only state anxiety scores decreased at post-treatment, with the difference reaching statistical significance. Conclusions: MBSR produces higher improvements in emotional states and quality of life than those obtained following a psycho educational standard procedure. However, it cannot be stated that MBSR must be always the intervention to be applied in all cases, since it is not clear that all patients could follow the guidelines, tasks and exercices required by this technique.
Leon C.,Institute Oncologic del Valles |
Jovell E.,Consorci Sanitari de Terrassa |
Mirapeix R.,Hospital Parc Tauli Of Sabadell |
Arcusa A.,Institute Oncologic del Valles |
Blasco T.B.,Autonomous University of Barcelona
Psicooncologia | Year: 2012
Purpose: To state the rate of patients who would ask for psychological assistance, once they have known their diagnosis and treatment assigned. To find the profile of these patients considering their demographic, clinical and psychosocial features. Method: A sample of 236 patients assisted at Consorci Sanitari de Terrassa (CST) was assessed using a questionnaire which asked for demographic and social features, as well as for some psychological variables (mood states, coping problems, previous anxiety or depression disorders) during the months which followed the diagnosis. Results: 24% of patients were interested in receiving psychological assistance. These patients were younger, expressed mood alterations and coping difficulties, and did not have previous anxiety or depression disorders. There were no differences between patients who asked for psychological assistance and those who do not, in gender, educational level, social relationships, diagnostic, or prognosis. Months from the knowledge of diagnosis were also unrelated with desire of receiving psychological assistance. Conclusions: A definition of what does mean "psychological assistance" is needed in order to understand why only 22% of patients ask for this resource. Sociodemographic and clinical variables were unrelated with desire of receiving psychological assistance. Younger patients with psychological distress and without previous history of emotional disturbance are more prone to ask for psychological assistance.
Blanco A.,University of Santiago de Compostela |
de la Hoya M.,Hospital Clinico San Carlos |
Osorio A.,Human Genetics Group |
Diez O.,Autonomous University of Barcelona |
And 19 more authors.
PLoS ONE | Year: 2013
Background: The PALB2 gene, also known as FANCN, forms a bond and co-localizes with BRCA2 in DNA repair. Germline mutations in PALB2 have been identified in approximately 1% of familial breast cancer and 3-4% of familial pancreatic cancer. The goal of this study was to determine the prevalence of PALB2 mutations in a population of BRCA1/BRCA2 negative breast cancer patients selected from either a personal or family history of pancreatic cancer. Methods: 132 non-BRCA1/BRCA2 breast/ovarian cancer families with at least one pancreatic cancer case were included in the study. PALB2 mutational analysis was performed by direct sequencing of all coding exons and intron/exon boundaries, as well as multiplex ligation-dependent probe amplification. Results: Two PALB2 truncating mutations, the c.1653T>A (p.Tyr551Stop) previously reported, and c.3362del (p.Gly1121ValfsX3) which is a novel frameshift mutation, were identified. Moreover, several PALB2 variants were detected; some of them were predicted as pathological by bioinformatic analysis. Considering truncating mutations, the prevalence rate of our population of BRCA1/2-negative breast cancer patients with pancreatic cancer is 1.5%. Conclusions: The prevalence rate of PALB2 mutations in non-BRCA1/BRCA2 breast/ovarian cancer families, selected from either a personal or family pancreatic cancer history, is similar to that previously described for unselected breast/ovarian cancer families. Future research directed towards identifying other gene(s) involved in the development of breast/pancreatic cancer families is required. © 2013 Blanco et al.
Ruiz A.,Institute Universitari |
Llort G.,Institute Oncologic Del Valles |
Yague C.,Institute Oncologic Del Valles |
Baena N.,Institute Universitari |
And 6 more authors.
BioMed Research International | Year: 2014
High throughput methods such as next generation sequencing are increasingly used in molecular diagnosis. The aim of this study was to develop a workflow for the detection of BRCA1 and BRCA2 mutations using massive parallel sequencing in a 454 GS Junior bench top sequencer. Our approach was first validated in a panel of 23 patients containing 62 unique variants that had been previously Sanger sequenced. Subsequently, 101 patients with familial breast and ovarian cancer were studied. BRCA1 and BRCA2 exon enrichment has been performed by PCR amplification using the BRCA MASTR kit (Multiplicom). Bioinformatic analysis of reads is performed with the AVA software v2.7 (Roche). In total, all 62 variants were detected resulting in a sensitivity of 100%. 71 false positives were called resulting in a specificity of 97.35%. All of them correspond to deletions located in homopolymeric stretches. The analysis of the homopolymers stretches of 6 bp or longer using the BRCA HP kit (Multiplicom) increased the specificity of the detection of BRCA1 and BRCA2 mutations to 99.99%. We show here that massive parallel pyrosequencing can be used as a diagnostic strategy to test for BRCA1 and BRCA2 mutations meeting very stringent sensitivity and specificity parameters replacing traditional Sanger sequencing with a lower cost. © 2014 Anna Ruiz et al.
Bonet M.,Institute Oncologic del Valles CST HGC CSPT |
Godoy P.,University of Lleida |
Cambra M.J.,Hospital General Of Catalonia |
Mur E.,Institute Oncologic del Valles CST HGC CSPT |
And 9 more authors.
Reports of Practical Oncology and Radiotherapy | Year: 2015
Aim: The aim of the present study was to analyze the age of breast cancer patients managed with curative approach at the time of treatment with radiotherapy. Background: Breast cancer is the most frequent neoplasm in women. Little is known with regard to the age of patients at diagnosis, and some authors have suggested that breast cancer is now affecting women who are younger than before. Materials and methods: We performed a descriptive study of our series of breast cancer patients from 1998 to 2011. The age of patients, city of residence, year of treatment and uni- or bilateral location were extracted from the administrative database of the Radiation Oncology Department. The demographical and reference populational data were extracted from the Catalan Institute of Statistics. Results: 3382 patients were obtained. The mean age was 57.79 years. No statistical differences were observed in the mean age during the period of study (p > 0.05), nor in patients with bilateral neoplasias with regard to unilateral tumours (p > 0.5). Patients aged less than 30, 40, 50 and 65 years were 0.3%, 6.3%, 27.0% and 69.1%, respectively. The proportion of patients aged less, equal or more than 40 and 50 years was not statistically different. Conclusions: Breast cancer patients treated with adjuvant radiotherapy after radical surgery have not experienced significant changes in their mean age at treatment. The subgroups of patients that remain out of the mammographic screening programmes were unchanged as well. The observed differences can be explained by demographical disparities and by a probable increase in the indications for adjuvant radiotherapy. © 2014 Greater Poland Cancer Centre.
PubMed | Institute Oncologic del Valles and Corporacio Sanitaria Parc Tauli Institute Universitari
Type: | Journal: BioMed research international | Year: 2014
High throughput methods such as next generation sequencing are increasingly used in molecular diagnosis. The aim of this study was to develop a workflow for the detection of BRCA1 and BRCA2 mutations using massive parallel sequencing in a 454 GS Junior bench top sequencer. Our approach was first validated in a panel of 23 patients containing 62 unique variants that had been previously Sanger sequenced. Subsequently, 101 patients with familial breast and ovarian cancer were studied. BRCA1 and BRCA2 exon enrichment has been performed by PCR amplification using the BRCA MASTR kit (Multiplicom). Bioinformatic analysis of reads is performed with the AVA software v2.7 (Roche). In total, all 62 variants were detected resulting in a sensitivity of 100%. 71 false positives were called resulting in a specificity of 97.35%. All of them correspond to deletions located in homopolymeric stretches. The analysis of the homopolymers stretches of 6bp or longer using the BRCA HP kit (Multiplicom) increased the specificity of the detection of BRCA1 and BRCA2 mutations to 99.99%. We show here that massive parallel pyrosequencing can be used as a diagnostic strategy to test for BRCA1 and BRCA2 mutations meeting very stringent sensitivity and specificity parameters replacing traditional Sanger sequencing with a lower cost.